Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novo Nordisk |
---|---|
Information provided by: | Novo Nordisk |
ClinicalTrials.gov Identifier: | NCT00124293 |
The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.
Condition | Intervention |
---|---|
Traumatic Brain Injury |
Drug: activated recombinant human factor VII |
Study Type: | Observational |
Official Title: | A Multi Centre Observational Study to Evaluate the Incidence and Magnitude of Haemorrhagic Progression of Cerebral Contusions and the Identification of Important Safety Issues Following Traumatic Brain Injury |
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Study Director: | Brett Skolnick, PhD | Novo Nordisk |
Responsible Party: | Novo Nordisk A/S ( Public Access to Clinical Trials ) |
Study ID Numbers: | F7CBI-1587 |
Study First Received: | June 30, 2005 |
Last Updated: | November 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00124293 |
Health Authority: | United States: Institutional Review Board |
Craniocerebral Trauma Contusions Wounds and Injuries Disease Progression Disorders of Environmental Origin |
Central Nervous System Diseases Trauma, Nervous System Brain Diseases Brain Injuries |
Nervous System Diseases |